[go: up one dir, main page]

WO2019038995A1 - Dispositif de dissolution de médicament solide - Google Patents

Dispositif de dissolution de médicament solide Download PDF

Info

Publication number
WO2019038995A1
WO2019038995A1 PCT/JP2018/016727 JP2018016727W WO2019038995A1 WO 2019038995 A1 WO2019038995 A1 WO 2019038995A1 JP 2018016727 W JP2018016727 W JP 2018016727W WO 2019038995 A1 WO2019038995 A1 WO 2019038995A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid
water
treated
drug
solid drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2018/016727
Other languages
English (en)
Japanese (ja)
Inventor
太輔 五百崎
真二郎 野間
廣田　達哉
哲章 平山
ゆうこ 丸尾
藤田　浩史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panasonic Intellectual Property Management Co Ltd
Original Assignee
Panasonic Intellectual Property Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panasonic Intellectual Property Management Co Ltd filed Critical Panasonic Intellectual Property Management Co Ltd
Priority to CN201880055412.1A priority Critical patent/CN111065450A/zh
Priority to JP2019537918A priority patent/JPWO2019038995A1/ja
Publication of WO2019038995A1 publication Critical patent/WO2019038995A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F21/00—Dissolving
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage

Definitions

  • the present invention relates to a solid drug dissolving apparatus for dissolving a solid drug in water to be treated.
  • the solid drug is only placed on the solid drug support. Therefore, the displacement of the solid medicine occurs due to the flow of the water to be treated during use. As a result, the concentration of the drug with respect to the water to be treated may vary due to the variation in the method of dissolving the solid drug.
  • the present invention has been made in view of the problems of the prior art. And the object of the present invention is to provide a solid medicine dissolution apparatus which can control that the concentration to the treated water of a medicine changes.
  • a solid drug dissolving apparatus in a container unit and inside the container unit, has at least one communication hole, and is stacked vertically.
  • a solid drug support portion for supporting at least one solid drug, an introduction channel for guiding treated water from the outside of the container portion to the lower side of the solid drug support portion, and after passing through the at least one communication hole
  • An outlet flow path for guiding the water to be treated in contact with at least one solid drug to the outside of the container portion, and upward from the solid drug support around the at least one solid drug, the at least one solid drug
  • a displacement suppression unit that suppresses displacement of the drug.
  • ADVANTAGE OF THE INVENTION According to this invention, it can suppress that dispersion
  • Embodiment 1 of the present invention It is a longitudinal cross-sectional view of the solid medicine dissolving device of another example of Embodiment 1 of the present invention. It is a perspective view for demonstrating the solid medicine support of the solid medicine dissolution apparatus of other examples of Embodiment 1 of the present invention. It is a longitudinal cross-sectional view of the solid medicine dissolution apparatus of Embodiment 2 of the present invention. It is a perspective view for demonstrating the solid medicine support part of the solid medicine dissolution apparatus of Embodiment 2 of this invention. It is a perspective view for demonstrating the solid medicine support of the other example of the solid medicine dissolving apparatus of Embodiment 2 of the present invention. It is a longitudinal cross-sectional view of the solid medicine dissolution apparatus of Embodiment 3 of the present invention.
  • Embodiment 1 The solid medicine dissolving apparatus 100 according to Embodiment 1 will be described below with reference to FIGS. 1 to 7.
  • the solid medicine dissolving apparatus 100 includes a container part 120, a solid medicine supporting part 21, an introduction channel 11A, and a protrusion 22X as a positional deviation suppressing part, a solid medicine A storage space 11B and a lead-out channel 11C are provided.
  • the container unit 120 includes a container body 2 that constitutes a water tank, and a lid 1 attached to the upper end of the container body 2. The lid 1 is configured to be attached to the container body 2 or removed from the container body 2.
  • the introduction channel 11A is provided along the outer periphery of the cylindrical pipe 11 extending in the vertical direction, the disk-like flange 12 provided on the upper end of the cylindrical pipe 11, and It is shaped by an annular spacer 13.
  • the introduction channel 11A guides the water to be treated from the outside of the container portion 120 to the lower side of the solid medicine support portion 21.
  • the outlet channel 11C guides the water to be treated, which has come into contact with the at least one solid medicine CA after passing through the at least one communication hole 21A, 21B, to the outside of the container portion 120.
  • the solid medicine storage space 11B is a space where the solid medicine CA is held. At the time of use of the solid medicine dissolving apparatus 100, the water to be treated flows from the introduction flow path 11A into the discharge flow path 11C via the solid medicine storage space 11B.
  • the introduction channel 11A has a T-shaped cross section, but if the treated water can be guided to the lower side of the solid drug support 21, a generally used cylindrical flow It may have any shape, such as the shape of the passage.
  • the outlet channel 11C is a space surrounding the inlet channel 11A having a T-shaped cross section, but any shape may be used as long as the water to be treated can flow down from the upper side of the solid drug support 21. It may be one.
  • the solid medicine support unit 21 is provided inside the container unit 120 and has at least one communication hole 21A, 21B.
  • the at least one communication hole 21A, 21B comprises four inner communication holes 21A and eight outer communication holes 21B.
  • the number of the communication holes 21A and 21B may be any number as long as the water to be treated can pass through the solid drug support 21 from the bottom to the top and contact the solid drug CA.
  • the introduction flow passage 11A communicates only with at least one communication hole 21A, 21B.
  • the solid drug support 21 supports one solid drug CA, as shown in FIG.
  • the solid medicine support unit 21 can also support a plurality of solid medicines CA stacked in the vertical direction.
  • the solid drug CA is a chlorine-based solid drug.
  • the protrusion 22 ⁇ / b> X as a positional deviation suppressing portion protrudes upward from the solid medicine support 21 around the solid medicine CA. Therefore, positional deviation of the solid medicine CA is suppressed. As a result, the concentration of the drug dissolved in the water to be treated can suppress the variation.
  • the protrusion 22 ⁇ / b> X serving as a positional deviation suppressing portion moves the water to be treated to the side so that the water to be treated is not accumulated on the solid drug support 21. It has the notch 22Y which leads. That is, the displacement control unit of the present embodiment is not necessarily formed over the entire circumference of the solid medicine CA. Further, when the water to be treated does not flow into the solid drug dissolving apparatus 100, the damage treated water surface is positioned at a height not to contact the solid drug CA. Therefore, when the water to be treated does not flow, the concentration of the drug dissolved in the water to be treated is prevented from being extremely high partially when the solid drug CA continues to be in contact with the water to be treated. Can.
  • the protrusion 22 ⁇ / b> X as the positional displacement suppressing portion may have one notch 22 ⁇ / b> Y only in a part of the annular protrusion in a plan view.
  • the protrusions 22 ⁇ / b> X as the displacement suppressing portion may have a height capable of suppressing displacement of the plurality of solid medicines CA stacked in the vertical direction.
  • the positional deviation curb may include three rod-like portions 30 provided at a distance from each other around at least one solid drug CA. Even with this configuration, it is possible to suppress that the concentration of the drug dissolved in the water to be treated is partially extremely high when the at least one disk-shaped solid drug CA continues to be in contact with the water to be treated. it can. According to at least three or more rod-shaped portions 30, particularly when the plurality of disc-shaped solid agents CA are stacked in the vertical direction, the plurality of disc-shaped solid agents CA can be prevented without obstructing the flow of water to be treated. Positional displacement can be effectively suppressed. When the solid drug CA has a disk shape, the number of rod-shaped portions 30 may be three or more in order to suppress the positional deviation of the solid drug CA.
  • the positional displacement suppression part is a projection 22X having a notch 22Y, the water to be treated does not accumulate on the solid drug support part 21. Therefore, in the present embodiment, the bypass flow passage which directly connects the introduction flow passage 11A and the discharge flow passage 11C described in the second embodiment described later is unnecessary.
  • the positional displacement suppressing portion is a plurality of protruding portions 22X having notches 22Y between each other.
  • the positional displacement suppressing portion may be an annular ring or a frame having no notch. It may be a peripheral portion having a shape.
  • the positional deviation suppressing portion is a peripheral edge portion provided to surround at least one solid drug CA all around the periphery of the at least one solid drug CA. 22 That is, the positional deviation suppression unit does not have the notch 22Y described in the first embodiment.
  • the solid medicine dissolving apparatus 100 is provided with a bypass channel 110 which directly leads the water to be treated from the introduction channel 11A to the outlet channel 11C. Therefore, instead of the annular spacer 13, a plurality of spacers 13X are provided, and a gap formed between the plurality of spacers 13X constitutes a bypass flow passage 110.
  • the solid medicine dissolving apparatus 100 according to the present embodiment differs from the solid medicine dissolving apparatus 100 according to the first embodiment in the points described above.
  • the peripheral portion 22 has an annular shape extending circumferentially, but may have a shape extending along the circumference of a square, a rectangle, or an ellipse.
  • the water to be treated flows in the solid drug dissolving apparatus 100
  • the water to be treated passes from the introduction flow passage 11A through the communication holes 22A and 22B.
  • the outlet channel 11C it contacts the solid drug CA.
  • solid medicine CA dissolves in treated water.
  • the water to be treated flows from the introduction channel 11A through the bypass channel 110. It is led to the road 11C. Therefore, when the water to be treated does not flow in the solid drug dissolving apparatus 100, the water surface of the water to be treated is positioned below the solid drug CA.
  • the solid medicine dissolving apparatus 100 transfers the introduction channel 11A to the outlet channel 11C. You may have the bypass flow path 110 which leads a to-be-treated water directly.
  • the container unit 120 includes the container body 2 constituting a water tank and the lid 1 attached to the upper end of the container body 2.
  • the lid 1 extends downward from the lower surface of the lid 1 as shown in FIG. 11, and the positional deviation of at least one solid drug CA around at least one solid drug CA.
  • a positional deviation limiting unit 40 which limits
  • the solid medicine dissolving apparatus 100 according to the present embodiment differs from the solid medicine dissolving apparatus 100 according to the first or second embodiment in this respect. According to the solid medicine dissolving apparatus 100 of the present embodiment, the movement of the solid medicine CA positioned on the upper side of the plurality of solid medicines CA stacked by the positional deviation limiting unit 40 can be restricted.
  • the distance between the protrusion 22X (or the peripheral edge 22) as the displacement suppression portion and the displacement restriction portion 40 is smaller than the thickness of each of the at least one solid medicine CA. Therefore, at the beginning of use of the solid drug CA, the solid drug CA passes through the gap C between the peripheral edge portion 22 (or the protrusion 22X) as the displacement restraining portion and the displacement displacing portion 40 and is led out 11C. From flowing out to the outside of the container portion 120 is suppressed.
  • the positional deviation limiting unit 40 is three rod-like portions as shown in FIG.
  • the positional deviation limiting unit 40 is provided around the at least one solid medicine CA so as to limit the positional deviation of the at least one solid medicine CA, the cylindrical shape as shown in FIG. It may be a part.
  • the solid medicine dissolving apparatus 100 includes a container part 120, a solid medicine support part 21, an introduction flow path 11A, a positional deviation suppression part (22, 22X, 30), and a discharge flow path 11C.
  • the solid drug support unit 21 is provided inside the container unit 120, has at least one communication hole 21A, 21B, and supports at least one solid drug CA so as to be vertically stacked.
  • the introduction channel 11A guides the water to be treated from the outside of the container portion 120 to the lower side of the solid medicine support portion 21.
  • the outlet channel 11C guides the water to be treated, which has come into contact with the at least one solid medicine CA after passing through the at least one communication hole 21A, 21B, to the outside of the container portion 120.
  • the positional deviation suppressing unit (22, 22X, 30) protrudes upward from the solid medicine support 21 around the at least one solid medicine CA, and suppresses the positional deviation of the at least one solid medicine CA. According to this configuration, since the positional deviation of at least one solid drug CA is suppressed, it is possible to suppress the variation in the concentration of the drug dissolved in the water to be treated.
  • the positional displacement suppression unit (22, 22X, 30) has a notch 22Y that guides the water to the side so that the water does not accumulate on the solid drug support 21. It is also good. According to this configuration, when the at least one solid drug CA continues to be in contact with the water to be treated, it is possible to suppress that the concentration of the drug dissolved in the water to be treated is partially extremely high.
  • the positional deviation prevention unit (22, 22X, 30) may include at least three bar-shaped portions 30 provided at a distance from each other around at least one solid drug CA. Even with this configuration, it is possible to suppress that the concentration of the drug dissolved in the water to be treated is partially extremely high when the at least one disk-shaped solid drug CA continues to be in contact with the water to be treated. it can.
  • the positional deviation of the plurality of disk-shaped solid drugs CA is prevented without obstructing the flow of the water to be treated as much as possible. It can be effectively suppressed.
  • the positional deviation suppressing portion (22, 22X, 30) may be a peripheral portion 22 provided to surround the at least one solid drug CA all around the at least one solid drug CA.
  • the solid medicine dissolving apparatus 100 it is preferable that the solid medicine dissolving apparatus 100 have a bypass channel 110 which directly leads the water to be treated from the introduction channel 11A to the outlet channel 11C. Also by this configuration, when the solid drug CA continues to be in contact with the water to be treated, it is possible to suppress that the concentration of the drug dissolved in the water to be treated is partially extremely high.
  • the container part 120 contains the container main-body part 2 which comprises a water tank, and the cover part 1 attached to the upper end of the container main-body part 2.
  • the lid portion 1 includes a positional deviation limiting portion 40 which extends downward from the lower side surface of the lid portion 1 and which restricts positional deviation of the at least one solid medicine CA around the at least one solid medicine CA. It is also good. According to this, the movement of the upper part of the plurality of solid medicines CA stacked by the positional deviation limiting unit 40 can be restricted.
  • the distance between the positional displacement suppressing portion (22, 22X, 30) and the positional displacement limiting portion 40 be smaller than the thickness of each of the at least one solid drug CA. According to this configuration, at least one solid medicine CA passes through the gap C between the positional displacement suppressing portion (22, 22X, 30) and the positional displacement limiting portion 40, and the outside of the container portion 120 from the outlet channel 11C. It can be suppressed to flow out.
  • Each of the at least one solid drug CA may be a chlorinated solid drug. According to this, chlorine can be dissolved in the water to be treated at a constant rate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hydrology & Water Resources (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental & Geological Engineering (AREA)
  • Water Supply & Treatment (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Le dispositif de dissolution de médicament solide (100) de l'invention est équipé : d'une partie support de médicament solide (21) qui est agencée dans une partie interne d'une partie réceptacle (120), qui possède au moins un orifice de communication (21A, 21B), et qui supporte au moins un médicament solide (CA) de manière à créer un empilement vertical ; d'un trajet d'introduction (11A) qui guide une eau à traiter depuis une partie externe de la partie réceptacle (120) vers le côté inférieur de la partie support de médicament solide (21) ; d'un trajet de décharge (11C) qui guide vers la partie externe de la partie réceptacle (120) l'eau à traiter en contact avec le ou les médicaments solides (CA) après passage au travers du ou des orifices de communication (21A, 21B) ; et d'une partie saillie (22X) qui forme un relief de la partie support de médicament solide (21) vers le haut, à la périphérie du ou des médicaments solides (CA), et qui sert de partie inhibant un décalage de position de la position du ou des médicaments solides (CA).
PCT/JP2018/016727 2017-08-25 2018-04-25 Dispositif de dissolution de médicament solide Ceased WO2019038995A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880055412.1A CN111065450A (zh) 2017-08-25 2018-04-25 固形药剂溶解装置
JP2019537918A JPWO2019038995A1 (ja) 2017-08-25 2018-04-25 固形薬剤溶解装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-162342 2017-08-25
JP2017162342 2017-08-25

Publications (1)

Publication Number Publication Date
WO2019038995A1 true WO2019038995A1 (fr) 2019-02-28

Family

ID=65439073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/016727 Ceased WO2019038995A1 (fr) 2017-08-25 2018-04-25 Dispositif de dissolution de médicament solide

Country Status (3)

Country Link
JP (1) JPWO2019038995A1 (fr)
CN (1) CN111065450A (fr)
WO (1) WO2019038995A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020195368A1 (fr) * 2019-03-27 2020-10-01 パナソニックＩｐマネジメント株式会社 Dispositif de dissolution chimique
JP2021023834A (ja) * 2019-07-31 2021-02-22 パナソニックＩｐマネジメント株式会社 水処理装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5882834U (ja) * 1981-11-30 1983-06-04 四国化成工業株式会社 固型塩素薬剤の溶解装置
JPS59169301U (ja) * 1983-04-26 1984-11-13 日産化学工業株式会社 浄化槽放流水用殺菌消毒錠剤
JPH07284771A (ja) * 1994-04-15 1995-10-31 Matsushita Electric Works Ltd イオン水生成器
JPH09271783A (ja) * 1996-04-09 1997-10-21 Hiroshi Miyazaki 飲料水殺菌装置
US20140054210A1 (en) * 2011-10-24 2014-02-27 Joseph A. King Stackable cartridges for bulk feeders
WO2018038090A1 (fr) * 2016-08-23 2018-03-01 栗田工業株式会社 Récipient pour agent de traitement de l'eau solide, ensemble récipient et procédé de traitement de l'eau

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5882834U (ja) * 1981-11-30 1983-06-04 四国化成工業株式会社 固型塩素薬剤の溶解装置
JPS59169301U (ja) * 1983-04-26 1984-11-13 日産化学工業株式会社 浄化槽放流水用殺菌消毒錠剤
JPH07284771A (ja) * 1994-04-15 1995-10-31 Matsushita Electric Works Ltd イオン水生成器
JPH09271783A (ja) * 1996-04-09 1997-10-21 Hiroshi Miyazaki 飲料水殺菌装置
US20140054210A1 (en) * 2011-10-24 2014-02-27 Joseph A. King Stackable cartridges for bulk feeders
WO2018038090A1 (fr) * 2016-08-23 2018-03-01 栗田工業株式会社 Récipient pour agent de traitement de l'eau solide, ensemble récipient et procédé de traitement de l'eau

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020195368A1 (fr) * 2019-03-27 2020-10-01 パナソニックＩｐマネジメント株式会社 Dispositif de dissolution chimique
JP2021023834A (ja) * 2019-07-31 2021-02-22 パナソニックＩｐマネジメント株式会社 水処理装置
JP7316492B2 (ja) 2019-07-31 2023-07-28 パナソニックＩｐマネジメント株式会社 水処理装置

Also Published As

Publication number Publication date
CN111065450A (zh) 2020-04-24
JPWO2019038995A1 (ja) 2020-09-03

Similar Documents

Publication Publication Date Title
WO2019038995A1 (fr) Dispositif de dissolution de médicament solide
US9885112B2 (en) Film forming apparatus
TWI752547B (zh) 非密閉式光罩收容裝置
US10874473B2 (en) Container
KR20170113218A (ko) 기판 처리 장치
JP6622407B2 (ja) 半導体処理装置およびその方法
KR102233330B1 (ko) 유체 분배 디바이스
US9165806B2 (en) Substrate treatment apparatus
WO2019038993A1 (fr) Dispositif de dissolution de médicament solide
JP2011156022A (ja) 血液浄化用カラム
CN101291725B (zh) 用于设备的气液相混合物分配器装置
JP2016164973A5 (fr)
CN102430366A (zh) 包括穿有不同类型孔的射流破碎器托盘的用于分布多相混合物的装置
EP2969870B1 (fr) Procédé pour distribuer des produits solides
BR112017019822B1 (pt) Sistema e método para proteção de uma membrana do respiradouro
JP2014014381A (ja) 薬液容器用ノズル
EP3342481B1 (fr) Distributeur et réacteur catalytique à flux descendant comprenant celui-ci
CN103028167B (zh) 一种用于输液器滴斗的气泡过滤装置
KR101561784B1 (ko) 카세트 이송 장치
KR101917377B1 (ko) 가스 분사 노즐
US10537866B2 (en) Scale collection device for downflow reactors
JP3162149U (ja) フィルタ装置
JP2014201346A (ja) 膜モジュールの梱包材
JP6652862B2 (ja) 原子炉
JP2016065788A (ja) 汚染水処理用吸着塔及び汚染水処理方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18848537

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019537918

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18848537

Country of ref document: EP

Kind code of ref document: A1